Drug Trials Snapshot: VANRAFIA

Summary

VANRAFIA is an endothelin type A receptor antagonist that is indicated to reduce proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk o...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage